Lilly Commits $3 Billion to Expand Supply of Weight-Loss Drug

In a significant move aimed at addressing the soaring demand for its weight-loss medication, Eli Lilly has announced plans to allocate $3 billion towards expanding the production capacity of its breakthrough drug, tirzepatide. This decision comes as obesity rates continue to rise globally, and the pharmaceutical company seeks to meet the needs of an increasing number of patients looking for effective weight management solutions.

Continue reading